ATE363288T1 - Verwendung von interleukin-18-inhibitoren zur hemmung von tumormetastasierung - Google Patents

Verwendung von interleukin-18-inhibitoren zur hemmung von tumormetastasierung

Info

Publication number
ATE363288T1
ATE363288T1 AT00944201T AT00944201T ATE363288T1 AT E363288 T1 ATE363288 T1 AT E363288T1 AT 00944201 T AT00944201 T AT 00944201T AT 00944201 T AT00944201 T AT 00944201T AT E363288 T1 ATE363288 T1 AT E363288T1
Authority
AT
Austria
Prior art keywords
interleukin
inhibitors
tumor metastasis
inhibit tumor
inhibit
Prior art date
Application number
AT00944201T
Other languages
German (de)
English (en)
Inventor
Charles Dinarello
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Application granted granted Critical
Publication of ATE363288T1 publication Critical patent/ATE363288T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00944201T 1999-07-22 2000-07-17 Verwendung von interleukin-18-inhibitoren zur hemmung von tumormetastasierung ATE363288T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL13104799A IL131047A0 (en) 1999-07-22 1999-07-22 Use of il-18 inhibitors

Publications (1)

Publication Number Publication Date
ATE363288T1 true ATE363288T1 (de) 2007-06-15

Family

ID=11073044

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00944201T ATE363288T1 (de) 1999-07-22 2000-07-17 Verwendung von interleukin-18-inhibitoren zur hemmung von tumormetastasierung

Country Status (31)

Country Link
US (1) US7741276B2 (enExample)
EP (1) EP1206274B1 (enExample)
JP (1) JP4827352B2 (enExample)
KR (1) KR100682219B1 (enExample)
CN (1) CN1173736C (enExample)
AR (1) AR024907A1 (enExample)
AT (1) ATE363288T1 (enExample)
AU (1) AU782478B2 (enExample)
BG (1) BG65800B1 (enExample)
BR (1) BR0012675A (enExample)
CA (1) CA2380216C (enExample)
CY (1) CY1107932T1 (enExample)
CZ (1) CZ302114B6 (enExample)
DE (2) DE1206274T1 (enExample)
DK (1) DK1206274T3 (enExample)
EA (1) EA005419B1 (enExample)
EE (1) EE04838B1 (enExample)
ES (1) ES2186596T3 (enExample)
HK (1) HK1048248B (enExample)
HU (1) HU228780B1 (enExample)
IL (2) IL131047A0 (enExample)
MX (1) MXPA02000838A (enExample)
NO (1) NO329827B1 (enExample)
NZ (1) NZ516535A (enExample)
PL (1) PL202477B1 (enExample)
PT (1) PT1206274E (enExample)
SK (1) SK287522B6 (enExample)
TR (1) TR200200169T2 (enExample)
UA (1) UA73745C2 (enExample)
WO (1) WO2001007480A2 (enExample)
ZA (1) ZA200200390B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120011898A (ko) * 2000-02-10 2012-02-08 아보트 러보러터리즈 사람 인터류킨-１８에 결합하는 항체 및 이를 제조하고 사용하는 방법
CA2424983A1 (en) 2000-10-11 2002-04-18 Viron Therapeutics, Inc. Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
UA85531C2 (uk) * 2001-05-16 2009-02-10 Йеда Рисерч Энд Дивелопмент Ко. Лтд. Застосування il-18 інгібіторів для лікування або попередження пов'язаної з сепсисом дисфункції серця
RU2225720C1 (ru) * 2002-08-12 2004-03-20 Научно-исследовательский институт онкологии Томского научного центра СО РАМН Средство, повышающее противоопухолевую и антиметастатическую активность циклофосфана
KR101015682B1 (ko) * 2002-10-08 2011-02-22 아레스 트레이딩 에스.에이. Ｉｌ-18ｂｐ에 결합할 수 있고 제 2 사이토킨의 활성을저해할 수 있는 사이토킨의 용도
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
DK1885753T3 (da) 2005-06-03 2011-10-03 Ares Trading Sa Fremstilling af rekombinant II-18-proteiner
HRP20110948T1 (hr) 2005-06-10 2012-01-31 Ares Trading S.A. Postupak za pročišćavanje il-18 vezujućeg proteina
CL2008002153A1 (es) 2007-07-24 2009-06-05 Amgen Inc Anticuerpo aislado o fragmanto de unión de antigeno del mismo que se une al receptor de il-18 (il-18r); molecula de ácido nucleico codificante; celula huesped que la comprende; composición farmaceutica; uso médico para tratar o prevenir una condición asociada con il-18r; método in vitro para inhibir la unión de il-18 al il-18r.
US9812033B2 (en) * 2013-03-06 2017-11-07 Venkatesh R. Chari Tactile graphic display
EP4493195A1 (en) 2022-03-15 2025-01-22 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
AU2024206448A1 (en) 2023-01-06 2025-08-21 Lassen Therapeutics, Inc. Anti-il-18bp antibodies
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE231915T1 (de) * 1992-09-02 2003-02-15 Isis Pharmaceuticals Inc Beeinflussing der zelladhäsie durch oligonukleotide
US7141393B2 (en) * 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
TR199902615T2 (xx) * 1997-03-18 2000-03-21 Basf Aktiengesellschaft Kortikosteroidlere verilen cevab�n mod�lasyonuna y�nelik metodlar ve kompozisyonlar.
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use

Also Published As

Publication number Publication date
JP2003505472A (ja) 2003-02-12
CZ302114B6 (cs) 2010-10-20
EA005419B1 (ru) 2005-02-24
ES2186596T3 (es) 2007-11-16
HK1048248A1 (en) 2003-03-28
CY1107932T1 (el) 2013-09-04
EE200200032A (et) 2003-02-17
AR024907A1 (es) 2002-10-30
BRPI0012675B8 (enExample) 2021-05-25
TR200200169T2 (tr) 2002-06-21
KR100682219B1 (ko) 2007-02-12
CA2380216A1 (en) 2001-02-01
EE04838B1 (et) 2007-06-15
PL202477B1 (pl) 2009-06-30
HUP0202107A2 (en) 2002-10-28
BR0012675A (pt) 2002-04-09
BRPI0012675B1 (pt) 2001-02-01
IL131047A0 (en) 2001-01-28
MXPA02000838A (es) 2002-07-30
NO20020153D0 (no) 2002-01-11
EP1206274A2 (en) 2002-05-22
ZA200200390B (en) 2003-04-30
NO20020153L (no) 2002-03-11
DE60035049T2 (de) 2007-09-27
ES2186596T1 (es) 2003-05-16
UA73745C2 (en) 2005-09-15
AU782478B2 (en) 2005-08-04
SK287522B6 (sk) 2011-01-04
DK1206274T3 (da) 2007-08-13
WO2001007480A3 (en) 2001-05-10
DE60035049D1 (de) 2007-07-12
BG65800B1 (bg) 2009-12-31
NZ516535A (en) 2004-04-30
US20080003216A1 (en) 2008-01-03
PL353732A1 (en) 2003-12-01
NO329827B1 (no) 2011-01-03
CZ2002195A3 (cs) 2002-06-12
HK1048248B (zh) 2005-04-22
CN1173736C (zh) 2004-11-03
EA200200189A1 (ru) 2002-12-26
US7741276B2 (en) 2010-06-22
EP1206274B1 (en) 2007-05-30
IL147675A (en) 2009-05-04
PT1206274E (pt) 2007-07-06
CA2380216C (en) 2012-01-31
JP4827352B2 (ja) 2011-11-30
DE1206274T1 (de) 2002-11-14
HU228780B1 (en) 2013-05-28
HUP0202107A3 (en) 2005-01-28
CN1364086A (zh) 2002-08-14
BG106311A (en) 2002-08-30
AU5843200A (en) 2001-02-13
WO2001007480A2 (en) 2001-02-01
SK882002A3 (en) 2002-07-02
KR20020027493A (ko) 2002-04-13

Similar Documents

Publication Publication Date Title
DE60110232D1 (de) Neue verwendung von lipase-inhibitoren
ATE363288T1 (de) Verwendung von interleukin-18-inhibitoren zur hemmung von tumormetastasierung
DE60232994D1 (de) Inhibitoren von mitotischem kinesin
DE60044004D1 (de) Verwendung von Omega-Carboxyaryl-substituierten Diphenylharnstoffen als raf-Kinase-Inhibitoren
DE60202077D1 (de) Spannungserhöhungs-schaltung mit bestimmung der versorgungsspannung zur kompensation von schwankungen der versorungsspannung beim lesen
DE60324805D1 (de) Inhibitoren von tyrosinkinasen
DE69940115D1 (de) Heterocyclische inhibitoren von p38
DE69807721D1 (de) Verwendungen von moleküle zur kontrolle der eisbildung
ATE418336T1 (de) Verwendung von i kappa b-kinase inhibitoren in der schmerztherapie
DE50012379D1 (de) Verwendung von nanoskaligen antischuppenwirkstoffen
ATE338552T1 (de) Verwendungen von et743 zur behandlung von krebs
DE60322898D1 (de) Verwendung von isoflavonen zur förderung des schlankheitseffekts
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
ATE390474T1 (de) Verwendung von polymerem material zur behandlung harter oberflächen
ATE261304T1 (de) Verwendung von eletriptan zur vorbeugung des wiederauftretens der migräne
DE60026644D1 (de) Verwendung von Ferulasäure zur Behandlung von Bluthochdruck
DE50311406D1 (de) Verwendung von Formkörpern
DE60327426D1 (de) Markierung von substraten
ATE303153T1 (de) Ibandroinsäure zur förderung der osseointegration der endoprothesen
DE60234717D1 (de) Verwendung von calmodulin zur förderung der knochenregeneration
DE10290563D2 (de) Mittel zur Hemmung von Tumorzellen
DE69828492D1 (de) Verwendung von isothiazolone zur reduzierung von emissionen von hcn
DE50011084D1 (de) Verwendung von azolen zur prävention von strahlen-induziertem hautkrebs
ATE450520T1 (de) Stereoselektive alkylierung von chirale 2-methyl- 4-geschützte piperazinen
EP1102599A4 (en) PROTEASE INHIBITORS SUITABLE FOR THE TREATMENT OF PSORIASIS

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1206274

Country of ref document: EP